Insider Selling: Genomic Health, Inc. (GHDX) CFO Sells 15,000 Shares of Stock

Genomic Health, Inc. (NASDAQ:GHDX) CFO G Bradley Cole sold 15,000 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $75.15, for a total transaction of $1,127,250.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, February 12th, G Bradley Cole sold 15,000 shares of Genomic Health stock. The stock was sold at an average price of $80.87, for a total transaction of $1,213,050.00.
  • On Tuesday, January 8th, G Bradley Cole sold 15,000 shares of Genomic Health stock. The stock was sold at an average price of $67.03, for a total transaction of $1,005,450.00.

GHDX traded down $1.99 on Friday, hitting $74.52. The company had a trading volume of 19,189 shares, compared to its average volume of 377,153. Genomic Health, Inc. has a 52-week low of $30.04 and a 52-week high of $92.18. The firm has a market capitalization of $2.80 billion, a PE ratio of 70.95 and a beta of 0.97.

Genomic Health (NASDAQ:GHDX) last announced its earnings results on Wednesday, February 20th. The medical research company reported $0.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.02. Genomic Health had a net margin of 6.52% and a return on equity of 16.86%. The business had revenue of $104.56 million during the quarter, compared to the consensus estimate of $101.55 million. During the same quarter last year, the firm earned $0.05 earnings per share. The business’s revenue for the quarter was up 22.0% on a year-over-year basis. Analysts anticipate that Genomic Health, Inc. will post 1.49 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Royce & Associates LP grew its position in Genomic Health by 22.8% in the 4th quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock worth $95,000 after purchasing an additional 273 shares during the period. Advisor Group Inc. grew its position in Genomic Health by 34.9% in the 4th quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock worth $129,000 after purchasing an additional 516 shares during the period. Pacer Advisors Inc. bought a new stake in Genomic Health in the 3rd quarter worth approximately $171,000. Quantamental Technologies LLC bought a new stake in Genomic Health in the 4th quarter worth approximately $180,000. Finally, Trexquant Investment LP bought a new stake in Genomic Health in the 3rd quarter worth approximately $202,000. 91.69% of the stock is owned by institutional investors.

A number of analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “strong-buy” rating and set a $97.00 target price (up from $86.00) on shares of Genomic Health in a report on Thursday, February 21st. ValuEngine upgraded shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 13th. Piper Jaffray Companies raised their price objective on shares of Genomic Health to $86.00 and gave the stock a “neutral” rating in a report on Thursday, February 21st. BidaskClub lowered shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 28th. Finally, Oppenheimer began coverage on shares of Genomic Health in a report on Wednesday, December 19th. They issued a “market perform” rating for the company. Nine investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $63.13.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2019/03/15/insider-selling-genomic-health-inc-ghdx-cfo-sells-15000-shares-of-stock.html.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

See Also: Ex-Dividend

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply